{"protocolSection": {"identificationModule": {"nctId": "NCT00337610", "orgStudyIdInfo": {"id": "0431-053"}, "secondaryIdInfos": [{"id": "2006_017"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus", "officialTitle": "A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy"}, "statusModule": {"statusVerifiedDate": "2016-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-06"}, "primaryCompletionDateStruct": {"date": "2007-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2007-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-06-14", "studyFirstSubmitQcDate": "2006-06-14", "studyFirstPostDateStruct": {"date": "2006-06-16", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-09-24", "resultsFirstSubmitQcDate": "2010-04-29", "resultsFirstPostDateStruct": {"date": "2010-05-27", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-05-11", "lastUpdatePostDateStruct": {"date": "2016-05-12", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic (blood sugar) control on metformin therapy."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus (T2DM)"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 190, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "sitagliptin 100 mg once a day (q.d.)/metformin \u22651500 mg a day", "type": "EXPERIMENTAL", "interventionNames": ["Drug: sitagliptin 100 mg q.d./metformin \u2265 1500 mg/day"]}, {"label": "sitagliptin 100 mg placebo q.d./ metformin \u2265 1500 mg/day", "type": "PLACEBO_COMPARATOR", "interventionNames": ["Drug: comparator: placebo to match sitagliptin 100 mg q.d./metformin \u2265 1500 mg/day"]}], "interventions": [{"type": "DRUG", "name": "sitagliptin 100 mg q.d./metformin \u2265 1500 mg/day", "description": "Patients will receive blinded sitagliptin 100 mg q.d. and open-label metformin \u2265 1500 mg/day for up to 30 weeks. Sitagliptin 100 mg q.d. and metformin \u2265 1500 mg/day will be administered as oral tablets.", "armGroupLabels": ["sitagliptin 100 mg once a day (q.d.)/metformin \u22651500 mg a day"], "otherNames": ["Januvia"]}, {"type": "DRUG", "name": "comparator: placebo to match sitagliptin 100 mg q.d./metformin \u2265 1500 mg/day", "description": "Patients will receive placebo to match sitagliptin 100 mg q.d. and open-label metformin \u2265 1500 mg/day for up to 30 weeks. Sitagliptin 100 mg q.d. and metformin \u2265 1500 mg/day will be administered as oral tablets.", "armGroupLabels": ["sitagliptin 100 mg placebo q.d./ metformin \u2265 1500 mg/day"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in A1C at Week 18", "description": "A1C was measured as a percent. Thus, this change from baseline reflects the Week 18 A1C percent minus the Week 0 A1C percent.", "timeFrame": "Baseline and Week 18"}], "secondaryOutcomes": [{"measure": "Change From Baseline in FPG at Week 18", "description": "Change from baseline at Week 18 is defined as Week 18 FPG minus Week 0 FPG.", "timeFrame": "Baseline and Week 18"}, {"measure": "Change From Baseline in 2 Hr-PMG at Week 18", "description": "Change from baseline at Week 18 is defined as Week 18 minus Week 0.", "timeFrame": "Baseline and Week 18"}, {"measure": "Change From Baseline in A1C at Week 30", "description": "A1C was measured as a percent. Thus, this change from baseline reflects the Week 30 A1C percent minus the Week 0 A1C percent.", "timeFrame": "Baseline and Week 30"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patient has type 2 diabetes mellitus\n* Males\n* Females who are highly unlikely to become pregnant\n* Patients poorly controlled while taking one or two oral antidiabetic medications\n\nExclusion Criteria:\n\n* Patient has a history of type 1 diabetes mellitus or history of ketoacidosis\n* Patient required insulin therapy within the prior 8 weeks\n* Patient is on or has been taking Thiazolidinediones (TZDs) such as Actos\u00ae (pioglitazone) or Avandia\u00ae (rosiglitazone) or is on or has been taking Byetta\u00ae (exenatide) within the prior 12 weeks of the screening visit", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "78 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "18194595", "type": "BACKGROUND", "citation": "Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM, Langdon RB, Stein PP, Alba M. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin. 2008 Feb;24(2):537-50. doi: 10.1185/030079908x260925."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Patients 18-78 years on oral single antihyperglycemic agent (AHA) (hemoglobin A1C \\[A1C\\] \u22658%) or metformin-based dual combination therapy (A1C 7.5-10.5%) were eligible to participate. Eligible patients underwent an up to 12-week metformin dose-titration/dose-stable period followed by a 2-week placebo run-in period prior to randomization.", "recruitmentDetails": "First Patient In: 21-Aug-2006; Last Patient Last Visit: 15-Aug-2007; Twenty-four medical clinics worldwide (12 in the United States, 2 in Israel, 3 in Mexico, 3 in Peru, and 4 in Austria).", "groups": [{"id": "FG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily in addition to ongoing treatment with open-label metformin \u2265 1500 mg/day."}, {"id": "FG001", "title": "Placebo", "description": "The Placebo group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo once daily in addition to ongoing treatment with open-label metformin \u2265 1500 mg/day."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "96"}, {"groupId": "FG001", "numSubjects": "94"}]}, {"type": "Completed Week 18", "achievements": [{"groupId": "FG000", "numSubjects": "89"}, {"groupId": "FG001", "numSubjects": "82"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "79"}, {"groupId": "FG001", "numSubjects": "80"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "14"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "5"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily in addition to ongoing treatment with open-label metformin \u2265 1500 mg/day."}, {"id": "BG001", "title": "Placebo", "description": "The Placebo group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo once daily in addition to ongoing treatment with open-label metformin \u2265 1500 mg/day."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "96"}, {"groupId": "BG001", "value": "94"}, {"groupId": "BG002", "value": "190"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "53.6", "spread": "9.5"}, {"groupId": "BG001", "value": "56.1", "spread": "9.5"}, {"groupId": "BG002", "value": "54.8", "spread": "9.5"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "47"}, {"groupId": "BG001", "value": "55"}, {"groupId": "BG002", "value": "102"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "49"}, {"groupId": "BG001", "value": "39"}, {"groupId": "BG002", "value": "88"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "40"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "84"}]}]}, {"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "4"}]}]}, {"title": "Hispanic", "categories": [{"measurements": [{"groupId": "BG000", "value": "31"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "55"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "25"}, {"groupId": "BG002", "value": "46"}]}]}]}, {"title": "2-Hour Post-Meal Glucose (2 hr PMG)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "288.7", "spread": "74.8"}, {"groupId": "BG001", "value": "286.7", "spread": "61.7"}, {"groupId": "BG002", "value": "287.7", "spread": "68.5"}]}]}]}, {"title": "Fasting Plasma Glucose (FPG)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "201.1", "spread": "46.2"}, {"groupId": "BG001", "value": "198.2", "spread": "44.6"}, {"groupId": "BG002", "value": "199.7", "spread": "45.3"}]}]}]}, {"title": "Hemoglobin A1C (A1C)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "9.3", "spread": "0.9"}, {"groupId": "BG001", "value": "9.1", "spread": "0.8"}, {"groupId": "BG002", "value": "9.2", "spread": "0.8"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in A1C at Week 18", "description": "A1C was measured as a percent. Thus, this change from baseline reflects the Week 18 A1C percent minus the Week 0 A1C percent.", "populationDescription": "The full-analysis-set (FAS) population included all patients with at least one dose of double-blind study therapy, and with a baseline value and \u22651 postbaseline value for this outcome. Data following glycemic rescue were treated as missing. Missing data were handled using the last observation carrying forward (LOCF) method.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent", "timeFrame": "Baseline and Week 18", "groups": [{"id": "OG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily in addition to ongoing treatment with open-label metformin \u2265 1500 mg/day."}, {"id": "OG001", "title": "Placebo", "description": "The Placebo group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo once daily in addition to ongoing treatment with open-label metformin \u2265 1500 mg/day."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}, {"groupId": "OG001", "value": "92"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.00", "lowerLimit": "-1.24", "upperLimit": "-0.75"}, {"groupId": "OG001", "value": "0.02", "lowerLimit": "-0.23", "upperLimit": "0.27"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Model terms: treatment; baseline; prior anti-hyperglycemic agent (AHA) \\[medication\\] (on Monotherapy AHA or on Metformin-based combination therapy)", "paramType": "Mean Difference (Net)", "paramValue": "-1.02", "ciPctValue": "95", "ciLowerLimit": "-1.36", "ciUpperLimit": "-0.67", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "1.19"}]}, {"type": "SECONDARY", "title": "Change From Baseline in FPG at Week 18", "description": "Change from baseline at Week 18 is defined as Week 18 FPG minus Week 0 FPG.", "populationDescription": "The full-analysis-set (FAS) population included all patients with at least one dose of double-blind study therapy, and with a baseline value and \u22651 postbaseline value for this outcome. Data following glycemic rescue were treated as missing. Missing data were handled using the LOCF method.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 18", "groups": [{"id": "OG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily in addition to ongoing treatment with open-label metformin \u2265 1500 mg/day."}, {"id": "OG001", "title": "Placebo", "description": "The Placebo group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo once daily in addition to ongoing treatment with open-label metformin \u2265 1500 mg/day."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "92"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-32.0", "lowerLimit": "-40.6", "upperLimit": "-23.3"}, {"groupId": "OG001", "value": "-6.5", "lowerLimit": "-15.1", "upperLimit": "2.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Model terms: treatment; baseline; prior anti-hyperglycemic medication (on Monotherapy AHA or on Metformin-based combination therapy)", "paramType": "Mean Difference (Net)", "paramValue": "-25.5", "ciPctValue": "95", "ciLowerLimit": "-37.7", "ciUpperLimit": "-13.3", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "42.2"}]}, {"type": "SECONDARY", "title": "Change From Baseline in 2 Hr-PMG at Week 18", "description": "Change from baseline at Week 18 is defined as Week 18 minus Week 0.", "populationDescription": "The full-analysis-set (FAS) population included all patients with at least one dose of double-blind study therapy, and with a baseline value and \u22651 postbaseline value for this outcome. Data following glycemic rescue were treated as missing. Missing data were handled using the LOCF method.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 18", "groups": [{"id": "OG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily in addition to ongoing treatment with open-label metformin \u2265 1500 mg/day."}, {"id": "OG001", "title": "Placebo", "description": "The Placebo group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo once daily in addition to ongoing treatment with open-label metformin \u2265 1500 mg/day."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "74"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-67.6", "lowerLimit": "-82.1", "upperLimit": "-53.2"}, {"groupId": "OG001", "value": "-13.5", "lowerLimit": "-28.2", "upperLimit": "1.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Model terms: treatment; baseline; prior anti-hyperglycemic medication (on Monotherapy AHA or on Metformin-based combination therapy)", "paramType": "Mean Difference (Net)", "paramValue": "-54.1", "ciPctValue": "95", "ciLowerLimit": "-74.7", "ciUpperLimit": "-33.6", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "63.8"}]}, {"type": "SECONDARY", "title": "Change From Baseline in A1C at Week 30", "description": "A1C was measured as a percent. Thus, this change from baseline reflects the Week 30 A1C percent minus the Week 0 A1C percent.", "populationDescription": "The full-analysis-set (FAS) population included all patients with at least one dose of double-blind study therapy, and with a baseline value and \u22651 postbaseline value for this outcome. Data following glycemic rescue were treated as missing. Missing data were handled using the LOCF method.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent", "timeFrame": "Baseline and Week 30", "groups": [{"id": "OG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily in addition to ongoing treatment with open-label metformin \u2265 1500 mg/day."}, {"id": "OG001", "title": "Placebo", "description": "The Placebo group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo once daily in addition to ongoing treatment with open-label metformin \u2265 1500 mg/day."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "95"}, {"groupId": "OG001", "value": "92"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.98", "lowerLimit": "-1.25", "upperLimit": "-0.70"}, {"groupId": "OG001", "value": "0.04", "lowerLimit": "-0.24", "upperLimit": "0.31"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Model terms: treatment; baseline; prior anti-hyperglycemic medication (on Monotherapy AHA or on Metformin-based combination therapy)", "paramType": "Mean Difference (Net)", "paramValue": "-1.01", "ciPctValue": "95", "ciLowerLimit": "-1.40", "ciUpperLimit": "-0.62", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "1.34"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Weeks 0 to 30", "eventGroups": [{"id": "EG000", "title": "Sitagliptin 100 mg", "description": "The Sitagliptin 100 mg group includes data from patients randomized to receive treatment with 100 mg oral tablets of sitagliptin once daily in addition to ongoing treatment with open-label metformin \u2265 1500 mg/day.", "seriousNumAffected": 0, "seriousNumAtRisk": 96, "otherNumAffected": 18, "otherNumAtRisk": 96}, {"id": "EG001", "title": "Placebo", "description": "The Placebo group includes data from patients randomized to receive treatment with oral tablets of sitagliptin-matching placebo once daily in addition to ongoing treatment with open-label metformin \u2265 1500 mg/day.", "seriousNumAffected": 5, "seriousNumAtRisk": 94, "otherNumAffected": 29, "otherNumAtRisk": 94}], "seriousEvents": [{"term": "Myocardial Ischaemia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 96}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 94}]}, {"term": "Upper Gastrointestinal Haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 96}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 94}]}, {"term": "Upper Limb Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 96}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 94}]}, {"term": "Adenocarcinoma Pancreas", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 96}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 94}]}, {"term": "Colon Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 96}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 94}]}, {"term": "Lymphoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 96}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 94}]}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 96}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 94}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 96}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 94}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 96}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 94}]}, {"term": "Blood Glucose Increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 96}, {"groupId": "EG001", "numAffected": 17, "numAtRisk": 94}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "Executive Vice President, Clinical and Quantitative Sciences", "organization": "Merck Sharp & Dohme Corp", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Austria", "Israel", "Mexico", "Peru", "United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}